{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T05:56:28Z","timestamp":1787896588916,"version":"build-2784847793"},"reference-count":52,"publisher":"Wiley","issue":"24","license":[{"start":{"date-parts":[[2021,11,7]],"date-time":"2021-11-07T00:00:00Z","timestamp":1636243200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Immune\u2010based combination therapies have revolutionized the first\u2010line treatment for advanced non\u2010small cell lung cancer (NSCLC). However, for the efficacy and safety, the best treatment option is still uncertain.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a Bayesian network meta\u2010analysis of randomized controlled trials (RCTs) to evaluate first\u2010line immune\u2010based combination therapies for advanced NSCLC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Fourteen trials involving 8467 patients were included. For the programmed cell death\u2010ligand 1 (PD\u2010L1) expression non\u2010selective patients, there were no significant differences among all the treatment modes for overall survival (OS), but the ranking profiles indicated that Immunotherapy\u00a0+\u00a0Immunotherapy\u00a0+\u00a0Chemotherapy (IO\u00a0+\u00a0IO\u00a0+\u00a0Chemo) was most likely to be the best mode (probability\u00a0=\u00a068%). Immunotherapy\u00a0+\u00a0Immunotherapy\u00a0+\u00a0Anti\u2010angiogenic therapy\u00a0+\u00a0Chemotherapy (IO\u00a0+\u00a0Anti\u2010angio\u00a0+\u00a0Chemo) was significantly better than most other treatment modes for progression\u2010free survival (PFS) with better objective response rate (ORR) and more obvious grade \u22653 treatment\u2010related adverse events (TRAEs). In PD\u2010L1\u2010high cohort, IO\u00a0+\u00a0Anti\u2010angio\u00a0+\u00a0Chemo seemed to be the best mode for OS, PFS, and ORR according to the ranking profiles. In PD\u2010L1\u2010intermediate and PD\u2010L1\u2010negative cohort, IO\u00a0+\u00a0IO\u00a0+\u00a0Chemo was inclined to be ranked first for prolonging OS (probability\u00a0=\u00a078%; 37%) and IO\u00a0+\u00a0Anti\u2010angio\u00a0+\u00a0Chemo was most likely to provide best PFS (probability\u00a0=\u00a096%; 100%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>IO\u00a0+\u00a0IO\u00a0+\u00a0Chemo has great potential to improve the OS regardless of histology type, especially in PD\u2010L1\u2010intermediate and PD\u2010L1\u2010negative cohort. IO\u00a0+\u00a0Anti\u2010angio\u00a0+\u00a0Chemo shows great superiority in improving the short\u2010term survival accompanied by increasing grade \u22653\u00a0TRAEs.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.4405","type":"journal-article","created":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T07:51:18Z","timestamp":1636357878000},"page":"9139-9155","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["First\u2010line immune\u2010based combination therapies for advanced non\u2010small cell lung cancer: A Bayesian network meta\u2010analysis"],"prefix":"10.1002","volume":"10","author":[{"given":"Ziyang","family":"Mao","sequence":"first","affiliation":[{"name":"Department of Medical Oncology The First Affiliated Hospital of Xi\u2019an Jiaotong University Xi\u2019an Shaanxi P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panpan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology The First Affiliated Hospital of Xi\u2019an Jiaotong University Xi\u2019an Shaanxi P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology The First Affiliated Hospital of Xi\u2019an Jiaotong University Xi\u2019an Shaanxi P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanlin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology The First Affiliated Hospital of Xi\u2019an Jiaotong University Xi\u2019an Shaanxi P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology The First Affiliated Hospital of Xi\u2019an Jiaotong University Xi\u2019an Shaanxi P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinyang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology The First Affiliated Hospital of Xi\u2019an Jiaotong University Xi\u2019an Shaanxi P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Jiao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology The First Affiliated Hospital of Xi\u2019an Jiaotong University Xi\u2019an Shaanxi P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology The First Affiliated Hospital of Xi\u2019an Jiaotong University Xi\u2019an Shaanxi P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics School of Public Health Xi'an Jiaotong University Health Science Center Xi\u2019an Shaanxi P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4412-3953","authenticated-orcid":false,"given":"Hui","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology The First Affiliated Hospital of Xi\u2019an Jiaotong University Xi\u2019an Shaanxi P.R. China"},{"name":"Key Laboratory of Environment and Genes Related to Diseases Xi'an Jiaotong University Ministry of Education of China Xi'an Shaanxi P.R. China"},{"name":"Centre for Translational Medicine The First Affiliated Hospital of Xi'an Jiaotong University Xi'an Shaanxi P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,11,7]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21551"},{"issue":"1","key":"e_1_2_8_3_1","article-title":"Global epidemiology of lung cancer","volume":"85","author":"Barta JA","year":"2019","journal-title":"Ann Glob Health"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21630"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2017.03.01"},{"key":"e_1_2_8_6_1","article-title":"Combination therapy with PD\u20101\/PD\u2010L1 blockade in non\u2010small cell lung cancer: strategies and mechanisms","volume":"219","author":"Huang MY","year":"2020","journal-title":"Pharmacol Ther"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.06.015"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03136"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.10.369"},{"key":"e_1_2_8_10_1","first-page":"233","article-title":"Nivolumab (N) + low\u2010dose ipilimumab (I) vs platinum\u2010doublet chemotherapy (Chemo) as first\u2010line (1L) treatment (TX) for advanced non\u2010small cell lung cancer (NSCLC): checkmate 227 part 1 final analysis","volume":"43","author":"Reck M","year":"2020","journal-title":"Oncology Research and Treatment"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.2292"},{"issue":"16","key":"e_1_2_8_12_1","article-title":"IMpower150 final analysis: efficacy of atezolizumab (atezo) + bevacizumab (bev) and chemotherapy in first\u2010line (1L) metastatic nonsquamous (nsq) non\u2010small cell lung cancer (NSCLC) across keysubgroups","volume":"80","author":"Socinski MA","year":"2020","journal-title":"Can Res"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071905"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1746112"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2020.02.14"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2385"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.03.028"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30167-6"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz453.004"},{"key":"e_1_2_8_21_1","first-page":"S215","article-title":"A randomized phase 3 study of camrelizumab plus chemotherapy as 1st line therapy for advanced\/metastatic non\u2010squamous non\u2010small cell lung cancer","volume":"14","author":"Zhou C","year":"2019","journal-title":"World Conference on Lung Cancer"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.08.004"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.2287"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.1577"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.7629"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.1578"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04605-x"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0116-x"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.01.035"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104621"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510665"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.08.608"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy275"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2018.29"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.2391"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.08.2020"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0402"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.08.019"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.4_suppl.102"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12102985"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.6_suppl.431"},{"key":"e_1_2_8_43_1","first-page":"41","article-title":"IMmotion151: a randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic Renal Cell Carcinoma (mRCC)","volume":"41","author":"Grullich C","year":"2018","journal-title":"Oncol Res Treatment"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-019-1192-1"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.12.033"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.01.018"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1159\/000458412"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.7150\/jca.21118"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2016.11.013"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.08.026"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31820b80ca"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI80011"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.5367"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.4405","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.4405","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.4405","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T05:05:15Z","timestamp":1693199115000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.4405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,7]]},"references-count":52,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1002\/cam4.4405"],"URL":"https:\/\/doi.org\/10.1002\/cam4.4405","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,7]]},"assertion":[{"value":"2021-07-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}